Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis.

[1]  M. Filetti,et al.  Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation , 2020, Journal for ImmunoTherapy of Cancer.

[2]  C. Criscitiello,et al.  Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. , 2020, European journal of cancer.

[3]  C. Criscitiello,et al.  Pre-treatment blood parameters predict efficacy from immunotherapy agents in early phase clinical trials. , 2020, The oncologist.

[4]  Andrew H. Beck,et al.  Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer , 2020, npj Breast Cancer.

[5]  Zhi Han,et al.  Deep-Learning–Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data , 2020, JCO clinical cancer informatics.

[6]  T. Owonikoko,et al.  Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials , 2020, Cancer.

[7]  A. Rowland,et al.  Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. , 2019, JAMA oncology.

[8]  G. Coukos,et al.  Immunotherapy in Ovarian Cancer: Are We There Yet? , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Curigliano,et al.  Recent advances in triple negative breast cancer: the immunotherapy era , 2019, BMC Medicine.

[10]  N. Tinari,et al.  A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable , 2019, Journal of Immunotherapy for Cancer.

[11]  T. Chan,et al.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.

[12]  I. Wolf,et al.  Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study , 2018, PloS one.

[13]  S. Vesely,et al.  Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade , 2018, Nature Medicine.

[14]  W. Shen,et al.  How to best assess abdominal obesity , 2018, Current opinion in clinical nutrition and metabolic care.

[15]  B. Caan,et al.  The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint. , 2018, Cancer research.

[16]  L. Dyck,et al.  Cancer, obesity and immunometabolism - Connecting the dots. , 2018, Cancer letters.

[17]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[18]  Matthew Wongchenko,et al.  Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. , 2018, The Lancet. Oncology.

[19]  J. Soria,et al.  Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). , 2017, European journal of cancer.

[20]  M. Wiese,et al.  Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers , 2017, British Journal of Cancer.

[21]  Lisa Martin,et al.  Subcutaneous adiposity is an independent predictor of mortality in cancer patients , 2017, British Journal of Cancer.

[22]  M. Atkins,et al.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy. , 2016, The Lancet. Oncology.

[23]  K. Dobbin,et al.  Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations , 2016, Journal of Immunotherapy for Cancer.

[24]  K. Dobbin,et al.  Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation , 2016, Journal of Immunotherapy for Cancer.

[25]  R. Jain,et al.  Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. , 2016, Cancer discovery.

[26]  A. Renehan,et al.  The Obesity Paradox in Cancer: a Review , 2016, Current Oncology Reports.

[27]  K. Flegal,et al.  Estimating population attributable fractions to quantify the health burden of obesity. , 2015, Annals of epidemiology.

[28]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[31]  D. Mathis.  Immunological goings-on in visceral adipose tissue. , 2013, Cell metabolism.

[32]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[33]  David Olmos,et al.  Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[35]  L. Sjöström,et al.  Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. , 1988, The American journal of clinical nutrition.

[36]  Frank E. Harrell,et al.  Prediction models need appropriate internal, internal-external, and external validation. , 2016, Journal of clinical epidemiology.

[37]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.